These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7911303)

  • 1. Effects of dopamine partial-agonist aminoergolines on dopamine metabolism in limbic and extrapyramidal regions of rat brain.
    Baldessarini RJ; Marsh ER; Huston-Lyons D
    Biochem Pharmacol; 1994 May; 47(10):1917-9. PubMed ID: 7911303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of limbic and extrapyramidal actions of intracerebrally injected dopamine by ergolines with partial D2 agonist activity in the rat.
    Campbell A; Baldessarini RJ; Yeghiayan S
    Brain Res; 1992 Oct; 592(1-2):348-52. PubMed ID: 1360315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actions of (+/-)-7-hydroxy-N,N-dipropylaminotetralin (7-OH-DPAT) on dopamine synthesis in limbic and extrapyramidal regions of rat brain.
    Booth RG; Baldessarini RJ; Marsh E; Owens CE
    Brain Res; 1994 Oct; 662(1-2):283-8. PubMed ID: 7859086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential action of bromocriptine on nigrostriatal versus mesolimbic dopaminergic neurons.
    Barton AC; Moore KE; Demarest KT
    J Neural Transm; 1987; 68(1-2):25-39. PubMed ID: 2879883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of isomers of hydroxyaporphines on dopamine metabolism in rat brain regions.
    Baldessarini RJ; Marsh ER; Kula NS; Zong RS; Gao YG; Neumeyer JL
    Biochem Pharmacol; 1990 Aug; 40(3):417-23. PubMed ID: 2383279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a partial D2-like receptor agonist on striatal dopamine autoreceptor functioning in preweanling rats.
    Yoshida ST; Baella SA; Stuebner NM; Crawford CA; McDougall SA
    Brain Res; 2006 Feb; 1073-1074():269-75. PubMed ID: 16427034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
    Meltzer LT; Caprathe BW; Christoffersen CL; Corbin AE; Jaen JC; Ninteman FW; Pugsley TA; Serpa KA; Shih YH; Whetzel SZ
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1177-89. PubMed ID: 8103791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
    J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions.
    Gygi SP; Gibb JW; Hanson GR
    J Pharmacol Exp Ther; 1994 Jul; 270(1):192-7. PubMed ID: 7913495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of synthesis-modulating nerve terminal autoreceptors on mesoamygdaloid and other mesolimbic dopamine neuronal populations.
    Kilts CD; Anderson CM; Ely TD; Nishita JK
    J Neurosci; 1987 Dec; 7(12):3961-75. PubMed ID: 3121804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912.
    Coward DM; Dixon AK; Urwyler S; White TG; Enz A; Karobath M; Shearman G
    J Pharmacol Exp Ther; 1990 Jan; 252(1):279-85. PubMed ID: 1967646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CY 208-243, a novel dopamine D-1 receptor agonist, fails to modify dopamine release in freely moving rats.
    Imperato A; Di Chiara G
    Eur J Pharmacol; 1989 Jan; 160(1):155-8. PubMed ID: 2565816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Selective analyzers of dopamine D2 receptors modulate serotonin metabolism in the striatum and nucleus accumbens of the rat brain during blockade of dopaminergic impulse flow].
    Gaĭnetdinov RR; Bogdanov MB; Kudrin VS; Raevskiĭ KS
    Biull Eksp Biol Med; 1992 Jun; 113(6):614-6. PubMed ID: 1359911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
    Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M
    Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential effect of noncataleptogenic neuroleptics on mesolimbic dopaminergic function.
    Bartholini G
    Adv Biochem Psychopharmacol; 1977; 16():607-11. PubMed ID: 18902
    [No Abstract]   [Full Text] [Related]  

  • 16. Autoreceptors mediate the inhibition of dopamine synthesis by bromocriptine and lisuride in rats.
    Tissari AH; Rossetti ZL; Meloni M; Frau MI; Gessa GL
    Eur J Pharmacol; 1983 Aug; 91(4):463-8. PubMed ID: 6413231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system.
    Bartholini G
    J Pharm Pharmacol; 1976 May; 28(5):429-33. PubMed ID: 6752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptors and ergot drugs. Evidence that an ergolene derivative is a differential agonist at subcortical limbic dopamine receptors.
    Fuxe K; Fredholm BB; Agnati LF; Corrodi H
    Brain Res; 1978 May; 146(2):295-311. PubMed ID: 647392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiological effects of putative autoreceptor-selective dopamine agonists on A10 dopamine neurons.
    Ackerman JM; Johansen PA; Clark D; White FJ
    J Pharmacol Exp Ther; 1993 May; 265(2):963-70. PubMed ID: 8098768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses of limbic and extrapyramidal substance P systems to nicotine treatment.
    Alburges ME; Frankel PS; Hoonakker AJ; Hanson GR
    Psychopharmacology (Berl); 2009 Jan; 201(4):517-27. PubMed ID: 18773198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.